BUSINESS

• Entry into Japan Biosimilar Market Will Take Time, Says BI Chairman
  April 21, 2014

• PIII Trial of Asthma Drug Benralizumab Kicks Off in Japan: Kyowa Kirin
  April 21, 2014

• NBI Postpones Launch of Anticancer Drug Giotrif until May 7
  April 21, 2014

• Kyowa Kirin, Amgen of US Terminate License Agreement for Mogamulizumab
  April 21, 2014

• Astellas Launches Japan’s 1st SGLT-2 Inhibitor Suglat
  April 18, 2014

• Sanofi Aims to Top SGLT-2 Inhibitor Market with Apleway
  April 18, 2014

• “MRs’ Manners” Are Opening Theme in Panel Discussion Held by MREAC
  April 18, 2014

• Sales of Diovan Fell 22% in 3rd Quarter of FY2013; Overall Growth of ARB Market Could Fall Short of Expectations
  April 18, 2014

• Boehringer Ingelheim Reports 14.1% Increase in Operating Profit to 2,114 Million Euro in 2013
  April 17, 2014

• Metal Found in Voltaren Product Again: Novartis
  April 17, 2014

• AZ Offers Sales Rep Jobs to over 100 New Graduates in FY2014
  April 16, 2014

• Eisai President Naito Awarded Honorary KBE
  April 16, 2014

• FY2015 Recruitment Plan: Eisai to Resume Offering Jobs to New Graduates
  April 15, 2014

• Novartis Pharma Notified Police about Metal Object Found in Voltaren Product
  April 15, 2014

• Hisamitsu Total Sales Up 5.5% but Domestic Ethical Drug Sales Down 1.8%
  April 14, 2014

• Patient Enrollment for PI Trial of Anticancer Drug HF10 in US Completed, Takara Bio
  April 14, 2014

• RaQualia, Asahi Kasei Pharma Conclude Joint Drug Discovery Research
  April 14, 2014

• 10% of Valsartan Franchise Prescriptions Switched to Other ARBs, Azilva, Micamlo Top Lists
  April 11, 2014

• Chugai Files NDA for Vemurafenib for Melanoma with BRAF Mutation, Roche Diagnostics Files for Companion Diagnostics
  April 11, 2014

• 17 Patients Who Took Xeplion Have Died since November Launch
  April 10, 2014

ページ

• « 先頭
• ‹ Prev
• …
• 566
• 567
• 568
• 569
• 570
• 571
• 572
• 573
• 574
• …
• Next ›
• 最終 »